KPRX
KIORA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$2.76
+3.37%Sep 8, 2026, 11:11 UTC
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 1, 2026.
Aug 19, 2026, 00:00 UTC
Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation an exclusive, sublicensable license to develop, manufacture, and commercialize its KIO-301 product for ophthalmology indications in South Korea, in exchange for a $1.0 million upfront fee, milestone payments, and double-digit royalties.
Aug 7, 2026, 11:00 UTC
Kiora Pharmaceuticals secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront, with remaining proceeds contingent on exercise of milestone-based warrants.
Source:Aug 7, 2026, 11:00 UTC
Kiora Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update on its clinical pipeline and corporate development activities.
Source:Jun 11, 2026, 00:00 UTC
Kiora Pharmaceuticals Inc elected Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle as Class II Directors effective June 10, 2026.